DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2011.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].
There are three US patents protecting this investigational drug and fifty-seven international patents.
Recent Clinical Trials for Mapracorat
|1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat||Bayer||Phase 1|
|Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days||Bausch & Lomb Incorporated||Phase 1|
|Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated||Phase 3|
Top disease conditions for Mapracorat
Top clinical trial sponsors for Mapracorat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mapracorat||Start Trial||5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents||Schering AG (Berlin, DE)||Start Trial|
|Mapracorat||Start Trial||Pharmaceutical composition for topical application of poorly soluble compounds||Intendis GmbH (Berlin, DE)||Start Trial|
|Mapracorat||Start Trial||Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma||Northwestern University (Evanston, IL)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|